Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus:: a randomized controlled trial

被引:40
|
作者
Ménard, J [1 ]
Payette, H [1 ]
Baillargeon, JP [1 ]
Maheux, P [1 ]
Lepage, S [1 ]
Tessier, D [1 ]
Ardilouze, JL [1 ]
机构
[1] Univ Sherbrooke, Ctr Hosp, Clin Res Ctr, Sherbrooke, PQ J1H 5N4, Canada
关键词
D O I
10.1503/cmaj.050054
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: National guidelines for managing diabetes set standards for care. We sought to determine whether a 1-year intensive multitherapy program resulted in greater goal attainment than usual care among patients with poorly controlled type 2 diabetes mellitus. Methods: We identified patients with poorly controlled type 2 diabetes receiving outpatient care in the community or at our hospital. Patients 30 - 70 years of age with a hemoglobin A(1C) concentration of 8% or greater were randomly assigned to receive intensive multitherapy (n = 36) or usual care (n = 36). Results: The average hemoglobin A(1C) concentration at entry was 9.1% (standard deviation [SD] 1%) in the intensive therapy group and 9.3% (SD 1%) in the usual therapy group. By 12 months, a higher proportion of patients in the intensive therapy group than in the control group had achieved Canadian Diabetes Association (CDA) goals for hemoglobin A(1C) concentrations (goal <= 7.0%: 35% v. 8%), diastolic blood pressure ( goal < 80 mm Hg: 64% v. 37%), low-density lipoprotein cholesterol (LDL-C) levels ( goal < 2.5 mmol/L: 53% v. 20%) and triglyceride levels ( goal < 1.5 mmol/L: 44% v. 14%). There were no significant differences between the 2 groups in attaining the targets for fasting plasma glucose levels, systolic blood pressure or total cholesterol: high-density lipoprotein cholesterol ratio. None of the patients reached all CDA treatment goals. By 18 months, differences in goal attainment were no longer evident between the 2 groups, except for LDL-C levels. Quality of life, as measured by a specific questionnaire, increased in both groups, with a greater increase in the intensive therapy group (13% [SD 10%] v. 6% [SD 13%], p < 0.003). Interpretation: Intensive multitherapy for patients with poorly controlled type 2 diabetes is successful in helping patients meet most of the goals set by a national diabetes association. However, 6 months after intensive therapy stopped and patients returned to usual care, the benefits had vanished.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [1] Efficacy and safety of Sancai powder in patients with type 2 diabetes mellitus: a randomized controlled trial
    Guo Qiang
    Zhang Hengyao
    Li Mindian
    Zhao Ziyi
    Luo Yunlin
    Luo Yulei
    Cao Wenzhai
    Zhao Huan
    Zhu Ranran
    Lei Xingxing
    Chen Huizhen
    Gan Huakui
    Zuo Zhihuang
    Chen Qi
    Shi Cuimei
    Zhang Xinli
    Guo Jian
    Zhong Sen
    Chen Qiu
    [J]. Journal of Traditional Chinese Medicine, 2016, 36 (05) : 640 - 648
  • [2] Efficacy and safety of Sancai powder in patients with type 2 diabetes mellitus: a randomized controlled trial
    Guo Qiang
    Zhang Hengyao
    Li Mindian
    Zhao Ziyi
    Luo Yunlin
    Luo Yulei
    Cao Wenzhai
    Zhao Huan
    Zhu Ranran
    Lei Xingxing
    Chen Huizhen
    Gan Huakui
    Zuo Zhihuang
    Chen Qi
    Shi Cuimei
    Zhang Xinli
    Guo Jian
    Zhong Sen
    Chen Qiu
    [J]. JOURNAL OF TRADITIONAL CHINESE MEDICINE, 2016, 36 (05) : 640 - 648
  • [3] Efficacy of Pharmaceutical Care in Patients with Type 2 Diabetes Mellitus and Hypertension: A Randomized Controlled Trial
    Wang, Weibo
    Geng, Lijuan
    Sun, Chenjing
    Li, Hui
    Wang, Jinying
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2022, 2022 : 7681404
  • [4] Efficacy of cinnamon in patients with type II diabetes mellitus: A randomized controlled clinical trial
    Zare, Roghayeh
    Nadjarzadeh, Azadeh
    Zarshenas, Mohammad Mehdi
    Shams, Mesbah
    Heydari, Mojtaba
    [J]. CLINICAL NUTRITION, 2019, 38 (02) : 549 - 556
  • [5] Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
    Oh, Tae Jung
    Yu, Jae Myung
    Min, Kyung Wan
    Son, Hyun Shik
    Lee, Moon Kyu
    Yoon, Kun Ho
    Song, Young Duk
    Park, Joong Yeol
    Jeong, In Kyung
    Cha, Bong Soo
    Kim, Yong Seong
    Baik, Sei Hyun
    Kim, In Joo
    Kim, Doo Man
    Kim, Sung Rae
    Lee, Kwan Woo
    Park, Jeong Hyung
    Lee, In Kyu
    Park, Tae Sun
    Choi, Sung Hee
    Park, Sung Woo
    [J]. DIABETES & METABOLISM JOURNAL, 2019, 43 (03) : 276 - 286
  • [6] Efficacy of Spirulina (Tahlab) in Patients of Type 2 Diabetes Mellitus (Ziabetus Shakri) - A Randomized Controlled Trial
    Alam, Anzar
    Quamri, Siddiqui
    Fatima, Sana
    Roqaiya, Mariyam
    Ahmad, Zaheer
    [J]. JOURNAL OF DIABETES & METABOLISM, 2016, 7 (10)
  • [7] Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
    Fulcher, Greg
    Matthews, David R.
    Perkovic, Vlado
    de Zeeuw, Dick
    Mahaffey, Kenneth W.
    Weiss, Robert
    Rosenstock, Julio
    Capuano, George
    Desai, Mehul
    Shaw, Wayne
    Vercruysse, Frank
    Meininger, Gary
    Neal, Bruce
    [J]. DIABETES THERAPY, 2015, 6 (03) : 289 - 302
  • [8] Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
    Greg Fulcher
    David R. Matthews
    Vlado Perkovic
    Dick de Zeeuw
    Kenneth W. Mahaffey
    Robert Weiss
    Julio Rosenstock
    George Capuano
    Mehul Desai
    Wayne Shaw
    Frank Vercruysse
    Gary Meininger
    Bruce Neal
    [J]. Diabetes Therapy, 2015, 6 : 289 - 302
  • [9] Quality of life in type 2 diabetes patients under intensive multitherapy
    Menard, J.
    Payette, H.
    Dubuc, N.
    Baillargeon, J. P.
    Maheux, P.
    Ardilouze, J. L.
    [J]. DIABETES & METABOLISM, 2007, 33 (01) : 54 - 60
  • [10] Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial
    Panahi, Yunes
    Khalili, Nahid
    Sahebi, Ebrahim
    Namazi, Soha
    Karimian, Maryam Saberi
    Majeed, Muhammed
    Sahebkar, Amirhossein
    [J]. INFLAMMOPHARMACOLOGY, 2017, 25 (01) : 25 - 31